The PSA has welcomed the Government’s long-awaited response to the Samsom Report.
“PSA noted that the Government accepted the Review Panel’s recommendation to develop a more comprehensive post-market monitoring scheme for medicines and medical devices and to include, for example, better integration and timely analysis of available datasets, including analysis of matched data from the PBS and other relevant datasets,” says PSA national president Joe Demarte.
“PSA’s submission to the Review highlighted that greater emphasis on pharmacovigilance activities was one avenue to further improve medicine use and health outcomes and had recommended better use of post-market surveillance data in Australia.”
The Government also accepted the Panel’s recommendation to review the Scheduling Policy Framework.
“PSA supported the recommendation to provide for the development of a formal risk-benefit methodology to assess scheduling applications in a streamlined manner and to enhance input from interested parties into the scheduling process,” Demarte says.
“PSA also supports the recommendation to review the advertising framework for therapeutic goods, including better management of complaints.
“We look forward to working with the Government on designing the implementation of the recommendations and to assist in delivering benefits from this important program of reform to improving the health of all Australians.”